JP2013522236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522236A5 JP2013522236A5 JP2012557280A JP2012557280A JP2013522236A5 JP 2013522236 A5 JP2013522236 A5 JP 2013522236A5 JP 2012557280 A JP2012557280 A JP 2012557280A JP 2012557280 A JP2012557280 A JP 2012557280A JP 2013522236 A5 JP2013522236 A5 JP 2013522236A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- biological sample
- cell
- lymphoma
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31367010P | 2010-03-12 | 2010-03-12 | |
| US61/313,670 | 2010-03-12 | ||
| PCT/US2011/028097 WO2011112933A1 (en) | 2010-03-12 | 2011-03-11 | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522236A JP2013522236A (ja) | 2013-06-13 |
| JP2013522236A5 true JP2013522236A5 (enExample) | 2014-04-24 |
Family
ID=43799739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557280A Pending JP2013522236A (ja) | 2010-03-12 | 2011-03-11 | レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20110223157A1 (enExample) |
| EP (1) | EP2544687A1 (enExample) |
| JP (1) | JP2013522236A (enExample) |
| KR (1) | KR20130038838A (enExample) |
| CN (1) | CN103068386A (enExample) |
| AR (1) | AR080505A1 (enExample) |
| AU (1) | AU2011224166B2 (enExample) |
| CA (1) | CA2792872A1 (enExample) |
| MX (1) | MX2012010367A (enExample) |
| TW (1) | TWI509247B (enExample) |
| WO (1) | WO2011112933A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| MX353482B (es) | 2011-04-29 | 2018-01-16 | Celgene Corp | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. |
| CA3136093C (en) | 2012-06-29 | 2025-07-08 | Celgene Corporation | METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| JP6347782B2 (ja) * | 2012-08-09 | 2018-06-27 | セルジーン コーポレイション | ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法 |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| US20150167097A1 (en) | 2012-09-20 | 2015-06-18 | Emory University | CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| AU2014254056B2 (en) * | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
| WO2015077058A2 (en) | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| WO2015085160A2 (en) * | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
| ES2969532T3 (es) * | 2014-05-19 | 2024-05-21 | Celgene Corp | 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| EP3347717A4 (en) | 2015-09-11 | 2019-06-05 | The Brigham and Women's Hospital, Inc. | PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS |
| US11384399B2 (en) | 2015-09-29 | 2022-07-12 | Htg Molecular Diagnostics, Inc. | Methods for subtyping diffuse large B-cell lymphoma (DLBCL) |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| WO2017120446A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| EP3484466A1 (en) * | 2016-07-13 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| US11529339B2 (en) | 2018-10-01 | 2022-12-20 | Celgene Corporation | Combination therapy for the treatment of cancer |
| US12400737B2 (en) * | 2018-10-10 | 2025-08-26 | Celgene Corporation | Methods of classifying diffuse large B-cell lymphoma |
| WO2025118133A1 (zh) * | 2023-12-05 | 2025-06-12 | 浙江普洛家园药业有限公司 | 一种(s)-来那度胺-5-位衍生物及其合成方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| EP0456950A1 (en) * | 1990-05-16 | 1991-11-21 | CONTRAVES ITALIANA S.p.A. | Actuator for restraint/release (R/R) devices, particularly for space applications |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| CN1981761B (zh) * | 2002-05-17 | 2011-10-12 | 细胞基因公司 | 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物 |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| US8367633B2 (en) * | 2007-08-06 | 2013-02-05 | University Of Rochester | Methods of treating B-cell cancers |
| WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| US20090148853A1 (en) * | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
-
2011
- 2011-03-11 EP EP11709300A patent/EP2544687A1/en not_active Withdrawn
- 2011-03-11 MX MX2012010367A patent/MX2012010367A/es not_active Application Discontinuation
- 2011-03-11 JP JP2012557280A patent/JP2013522236A/ja active Pending
- 2011-03-11 AU AU2011224166A patent/AU2011224166B2/en not_active Ceased
- 2011-03-11 CN CN2011800230775A patent/CN103068386A/zh active Pending
- 2011-03-11 CA CA2792872A patent/CA2792872A1/en not_active Abandoned
- 2011-03-11 KR KR1020127026568A patent/KR20130038838A/ko not_active Withdrawn
- 2011-03-11 AR ARP110100782A patent/AR080505A1/es unknown
- 2011-03-11 WO PCT/US2011/028097 patent/WO2011112933A1/en not_active Ceased
- 2011-03-11 US US13/046,527 patent/US20110223157A1/en not_active Abandoned
- 2011-03-11 TW TW100108463A patent/TWI509247B/zh not_active IP Right Cessation
-
2015
- 2015-03-03 US US14/636,949 patent/US20150174114A1/en not_active Abandoned
- 2015-09-18 US US14/858,594 patent/US20160008344A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522236A5 (enExample) | ||
| US11135225B2 (en) | Cancer treatments using combinations of CDK and ERK inhibitors | |
| Gild et al. | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells | |
| JP6047149B2 (ja) | 併用の医薬組成物およびその使用 | |
| JP2014510078A5 (enExample) | ||
| JP2020073520A (ja) | Ｗｅｅ１阻害剤を用いた癌を処置する方法 | |
| US20140296176A1 (en) | Combination cancer therapy with an hsp90 inhibitor and an antimetabolite | |
| AU2016262079A1 (en) | Combination of analogs or derivatives of dianhydrogalactitol with platinum-containing antineoplastic agents to treat cancer | |
| RU2013145524A (ru) | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона | |
| EP3024457A1 (en) | Compositions to improve the therapeutic benefit of bisantrene | |
| AU2020417223A1 (en) | Treatment of cancer with CDK12/13 inhibitors | |
| Lawasut et al. | Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets | |
| WO2023202563A1 (en) | Akt inhibitor in combination with pim kinase inhibitor | |
| US11155879B2 (en) | Method of predicting effects of CDC7 inhibitor | |
| WO2025076109A9 (en) | Use of elesclomol to treat clear-cell ovarian cancers with mutations in arid1a | |
| JP2019532934A (ja) | 卵巣癌を治療するための方法 | |
| WO2025207503A1 (en) | Inhibitors of polo-like kinase 4 (plk4) for the treatment of cancer | |
| TW202408514A (zh) | 用於治療癌症的表皮生長因子受體酪胺酸激酶抑制劑 | |
| CN116940365A (zh) | 慢性髓性白血病干细胞抑制剂 | |
| Albert | Histone Deacetylase Inhibitors are Effective Therapeutic Agents in Nasopharyngeal Carcinoma Cells | |
| HK40120025A (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| HK40020609A (en) | Method of predicting effects of cdc7 inhibitor | |
| HK40020609B (en) | Method of predicting effects of cdc7 inhibitor | |
| HK1226252A1 (en) | Cancer treatments using combinations of cdk and erk inhibitors |